Brief: Galecto Says First Patient Treated In Phase 2 Trial Of Oral Galectin-3 Inhibitor GB1211 In Liver Cirrhosis
13/09/2021 13:32
Sept 13 (Reuters) - Galecto Inc GLTO.O :
* GALECTO ANNOUNCES FIRST PATIENT TREATED IN PHASE 2 TRIAL
OF ORAL
GALECTIN-3 INHIBITOR GB1211 IN LIVER CIRRHOSIS
Source text for Eikon: ID:nGNX5n1TFM
Further company coverage: GLTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Damora Therapeutics
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing